LitAlert ~~ GeneLit.com

    • Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial.
    • Sabatier R, Rousseau F, Joly F, Cropet C, Montégut C, Frindte J, Cinier S, Guerra Alía EM, Polterauer S, Yoshida H, Vergote I, Colombo N, Hietanen S, Largillier R, Canzler U, Gratet A, Marmé F, Favier L, Pujade-Lauraine E, Ray-Coquard I.
    • Eur J Cancer. 2023 Jan 10. doi: 10.1016/j.ejca.2022.11.029. Epub ahead of print.

    Related:

    •• Identifier: NCT02477644: Platine, Avastin and OLAparib in 1st Line (PAOLA-1). (ClinicalTrials.gov . Accessed 2023 Jan 10.)

    • EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy.
    • Schmidt MK, Kelly JE, Brédart A, Cameron DA, de Boniface J, Easton DF, Offersen BV, Poulakaki F, Rubio IT, Sardanelli F, Schmutzler R, Spanic T, Weigelt B, Rutgers EJT.
    • Eur J Cancer. 2023 Jan 10. doi: 10.1016/j.ejca.2022.11.036. Epub ahead of print.

    • Novel Combination Regimens Strengthen and Expand Treatment Paradigm for Genitourinary Cancers.
    • Flaherty C, Dorff TB.
    • OncLive. 2023 Jan 10.

    • Ideaya to Launch PARG Inhibitor Trial in Homologous Recombination Repair-Deficient Cancers.
    • [No author given]
    • Precision Oncology News. 2023 Jan 9.

    • Targeting the DNA damage response for cancer therapy.
    • Curtin NJ.
    • Biochem Soc Trans. 2023 Jan 6:BST20220681. doi: 10.1042/BST20220681. Epub ahead of print.

    • Effect of CX3CL1/CX3CR1 gene polymorphisms on the clinical efficacy of carboplatin therapy in Han patients with ovarian cancer.
    • Wang XC, Zhou H, Jiang WJ, Jiang P, Sun YC, Ni WJ.
    • Front Genet. 2023 Jan 6;12:1065213. doi: 10.3389/fgene.2022.1065213.

    • Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations.
    • Kim J, Jeong K, Jun H, Kim K, Bae JM, Song MG, Yi H, Park S, Woo GU, Lee DW, Kim TY, Lee KH, Im SA.
    • Hum Genomics. 2023 Jan 6;17(1):2. doi: 10.1186/s40246-022-00447-3.

    • Oncologic Safety of Nipple-Sparing Mastectomy for Breast Cancer in BRCA Gene Mutation Carriers: Outcomes at 70 Months Median Follow-Up.
    • Webster AJ, Shanno JN, Santa Cruz HS, Kelly BN, Garstka M, Henriquez A, Specht MC, Gadd MA, Verdial FC, Nguyen A, Oseni TO, Coopey SB, Smith BL.
    • Ann Surg Oncol. 2023 Jan 5. doi: 10.1245/s10434-022-13006-w. Epub ahead of print.

    • Current Issues in the Management of Patients With Newly Diagnosed Advanced-Stage High-Grade Serous Carcinoma of the Ovary.
    • Penn CA, Alvarez RD.
    • JCO Oncol Pract. 2023 Jan 5:OP2200461. doi: 10.1200/OP.22.00461. Epub ahead of print.

    • Novel combination treatment of CDK 4/6 inhibitors with PARP inhibitors in triple negative breast cancer cells.
    • Guney Eskiler G, Ozman Z, Haciefendi A, Cansaran-Duman D.
    • Naunyn Schmiedebergs Arch Pharmacol. 2023 Jan 4. doi: 10.1007/s00210-022-02375-4. Epub ahead of print.

    • Re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.
    • Qi F, Xu Z, Zou Q.
    • Eur Urol. 2023 Jan 3:S0302-2838(22)02873-1. doi: 10.1016/j.eururo.2022.12.024. Epub ahead of print.
    • Letter

    Related:

    •• Original research:

    Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib.

    •• Reply:

    Reply to Feng Qi, Zicheng Xu, and Qing Zou's Letter to the Editor re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.

    • Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer.
    • Vera R, Ibarrola-de Andrés C, Adeva J, Pérez-Rojas J, García-Alfonso P, Rodríguez-Gil Y, Macarulla T, Serrano-Piñol T, Mondéjar R, Madrigal-Rubiales B.
    • Rev Esp Patol. 2023 Jan-Mar;56(1):32-44. doi: 10.1016/j.patol.2022.06.004. Epub 2022 Aug 26.
    • Review

    • A radiological complete response to pembrolizumab in a patient with metastatic upper urinary tract urothelial cancer and Lynch syndrome.
    • Oki R, Urasaki T, Ueki A, Inamura K, Komai Y, Takahashi S, Yonese J, Yuasa T.
    • IJU Case Rep. 2022 Oct 28 [eCollection 2023 Jan];6(1):33-36. doi: 10.1002/iju5.12542.

    • Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin.
    • Miyazawa Y, Shimizu T, Sekine Y, Arai S, Ohtsu A, Fujizuka Y, Nomura M, Koike H, Matsui H, Suzuki K.
    • IJU Case Rep. 2022 Oct 9 [eCollection 2023 Jan];6(1):37-40. doi: 10.1002/iju5.12543.

    Related:

    •• Letter:

    Editorial Comment on "Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin".

    • Interleukin-34 cancels anti-tumor immunity by PARP inhibitor.
    • Nakamura T, Kajihara N, Hama N, Kobayashi T, Otsuka R, Han N, Wada H, Hasegawa Y, Suzuki N, Seino KI.
    • J Gynecol Oncol. 2022 Dec 21. doi: 10.3802/jgo.2023.34.e25. Epub ahead of print.

    • Ideaya Biosciences Files IND With FDA for PARG Inhibitor.
    • [No author goven]
    • Precision Oncology News. 2022 Dec 12.